Chronic Benzodiazepine Use and Dementia Risk

Evidence for Dementia Association

Antimuscarinic medications are associated with increased risk of all-cause dementia and Alzheimer's disease in a cumulative, dose-dependent manner, and clinicians must discuss this potential risk with all patients prescribed these medications for chronic use 1
The Mayo Clinic guidelines specifically identify diazepam as a long-acting benzodiazepine to avoid, citing sedation, cognitive impairment, unsafe mobility with injurious falls, motor skill impairment, habituation, and withdrawal syndromes 2, 3

The American Geriatrics Society recommends tapering and avoiding benzodiazepines when possible, with consideration of safer alternatives including cognitive behavioral therapy for anxiety and sleep disorders, as outlined in the Beers Criteria and STOPP criteria 2, 3
The Mayo Clinic Proceedings advise benzodiazepine use solely on a short-term basis, with gradual tapering protocols for discontinuation 4

Cognitive-behavioral therapy, problem-solving therapy, interpersonal and supportive psychotherapy are recommended as first-line alternatives for anxiety 4
Antidepressants, such as paroxetine, may be considered as pharmacological alternatives for anxiety, though evidence for facilitating benzodiazepine tapering remains limited 4
For sleep disorders, addressing environmental factors including light control, noise reduction, and clustering of care activities is recommended 6

Gradual tapering over many weeks is essential for successful discontinuation of chronic diazepam, to prevent rebound symptoms and withdrawal syndromes including sleep disruption, as recommended by the Mayo Clinic Proceedings 2, 4
The American Academy of Sleep Medicine recommends patient-centered tapering protocols for patients on chronic diazepam, to prevent same-night relapse of symptoms 7